NEW YORK., April 3, 2023 – Sumitovant Biopharma Ltd. (“Sumitovant”) announced today that its parent company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”) will combine its

November 3, 2022 New pre-clinical data for SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia

Philadelphia, PA, May 17, 2022 – Spirovant Sciences, a gene therapy company developing treatments for inherited respiratory diseases, including cystic fibrosis (CF), announced today the launch of its new state-of-the-art research laboratory and corporate headquarters in Philadelphia.

Philadelphia, PA, November 4, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today presented SP-101,

Philadelphia, PA, October 28, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today announced that

PHILADELPHIA, Sept. 24, 2020 /PRNewswire/ — Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced that

PHILADELPHIA, May 13, 2020 /PRNewswire/ — Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis (CF), today

Accomplished Leaders in Gene Therapy Join Team PHILADELPHIA, PA, January 26, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for respiratory